Page 1 of 51Free preview · 1–5

About this document

Wellmark medical policy defining when 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D testing may be considered medically necessary for specified conditions affecting vitamin D metabolism. Testing that meets the policy criteria is limited to no more than annually; more frequent testing is considered not medically necessary. Routine testing and asymptomatic general-population screening are considered investigational. The document includes clinical background, an evidence review, professional guidelines, references, billing codes 82306, 82652, and 0038U, and policy history. Originally effective May 2011, it lists a February 2026 review date and February 2024 revision date. Coverage remains subject to the member’s benefit plan.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

Wellmark Blue Cross and Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. 1 © Wellmark, Inc. 02.04.34 Vitamin D Testing Original Effective Date: May 2011 Review Date: February 2026 Revised: February 2024 DISCLAIMER/INSTRUCTIONS FOR USE This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242. Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations, or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program. This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged, or new medical literature may have been published. This Medical Policy will be reviewed regularly and updated as scientific and medical literature becomes available; therefore, policies are subject to change without notice. Summary Description Vitamin D, also known as calciferol, is a fat-soluble vitamin that has a variety of physiologic effects, most prominently in calcium homeostasis and bone metabolism. In addition to the role it plays in bone metabolism, other physiologic effects include inhibition of smooth muscle proliferation, regulation of the renin-angiotensin system, a decrease in coagulation, and a decrease in inflammatory markers. Summary of Evidence For individuals who are asymptomatic without conditions or risk factors for which vitamin D treatment is recommended who receive testing of vitamin D levels, the evidence includes no randomized controlled trials (RCTs) of clinical utility (i.e., evidence that patient care including testing vitamin D levels versus care without testing vitamin D levels improves outcomes). Relevant outcomes are overall survival, test validity, symptoms, morbid events, and treatment-related morbidity. Indirect evidence of the potential utility of testing includes many RCTs and systematic reviews of vitamin D supplementation. There is a lack of standardized vitamin D testing strategies and cutoffs for vitamin D deficiency are not standardized or evidence based. In addition, despite the large quantity of evidence, considerable uncertainty remains about the beneficial health effects of vitamin D supplementation. Many RCTs have included participants

Page 2

Wellmark Blue Cross and Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. 2 © Wellmark, Inc. who were not vitamin D deficient at baseline and did not stratify results by baseline 25-hydroxyvitamin D level. Nonwhite race/ethnic groups are underrepresented in RCTs but have an increased risk of vitamin D deficiency. For skeletal health, there may be a small effect of vitamin D supplementation on falls, but there does not appear to be an impact on reducing fractures for the general population. The effect on fracture reduction may be significant in elderly women, and with higher doses of vitamin D. However, high doses of vitamin D may be associated with safety concerns in patients at risk for falls. For patients with asthma, there may be a reduction in severe exacerbations with vitamin D supplementation, but there does not appear to be an effect on other asthma outcomes. For patients who are pregnant, vitamin D supplementation may improve certain maternal and fetal outcomes. For overall mortality, there is also no benefit to the general population. RCTs evaluating extraskeletal, cancer, cardiovascular, and multiple sclerosis outcomes have not reported a statistically significant benefit for vitamin D supplementation. Although vitamin D toxicity and adverse events appear to be rare, few data on risks have been reported. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. However, for certain carefully selected individuals who have an associated defect risk in vitamin D metabolism, vitamin D testing may be considered medically necessary when the policy criteria is met. Additional Information Not applicable. OBJECTIVE The objective of this evidence review is to examine whether testing for vitamin D deficiency improves net health outcomes in symptomatic and asymptomatic individuals. PRIOR APPROVAL Not applicable. POLICY Medically Necessary: 25-hydroxyvitamin D (82306 or 0038U) 25-hydroxyvitamin D serum testing may be considered medically necessary in individuals in the evaluation of one of the following conditions with an associated defect risk in vitamin D metabolism: • Chronic kidney disease stage III or greater • Chronic liver disease • Granuloma forming disorders to include but not limited to: o Berylliosis o Coccidiomycosis o Histoplasmosis o Sarcoidosis o Tuberculosis • Glycogen storage disease • Graft versus host disease • HIV • Hypercalcemia • Hypocalcemia • Hyperparathyroidism • Hypoparathyroidism • Hypervitaminosis of vitamin D • Individuals receiving hyperalimentation

Page 3

Wellmark Blue Cross and Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. 3 © Wellmark, Inc. • Intestinal malabsorption to include but not limited to: o Bariatric surgery o Celiac Disease o Crohn’s (regional enteritis) o Cystic Fibrosis • Institutionalized individuals • Liver cirrhosis • Medication known to lower vitamin D levels to include but not limited to: o Anticonvulsants o Glucocorticoids • Myalgia • Myopathy related to endocrine disease • Myositis • Neoplastic hematologic disorders to include but not limited to: o Leukemia o Lymphoma • Obesity (Adults with a BMI > 30; Pediatrics with a BMI > 95th percentile) • Osteogenesis imperfecta • Osteopetrosis • Osteoporosis • Osteomalacia • Osteopenia • Pancreatic steatorrhea • Primary or miliary tuberculosis • Psoriasis • Renal, ureteral or urinary calculus • Rickets • Sarcoidosis • Systemic Lupus Erythematosus • Transplants Medically Necessary: 1,25-dihydroxyvitamin D (82652) 1,25-dihydroxyvitamin D may be considered medically necessary no more frequently than annually in the evaluation and monitoring of one of the following conditions with an associated defect risk in vitamin D metabolism: • Cat-scratch disease • Chronic kidney disease stage III or greater • Granuloma forming disorders to include but not limited to: o Berylliosis o Coccidiomycosis o Histoplasmosis o Sarcoidosis o Tuberculosis • Familial hypophosphatemia • Fontan surgery for congenital heart disease (i.e., Hypoplastic left heart syndrome, Tricuspid atresia, and Double outlet right ventricle) • Hypercalcemia of malignancy • Hyperparathyroidism • Hypoparathyroidism

Page 4

Wellmark Blue Cross and Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. 4 © Wellmark, Inc. • Individuals receiving hyperalimentation • Lymphoma • Neonatal hypocalcemia • Osteogenisis imperfecta • Osteomalacia • Osteopetrosis • Primary or miliary tuberculosis • Pseudohypoparathyroidism • Renal, ureteral, or urinary calculus • Rickets • Sarcoidosis • Systemic connective tissue disorder • Transplants Investigational: 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D The use of 1,25 dihydroxyvitamin D and 25-hydroxyvitamin D serum testing is considered investigational when the above criteria is not met and for all other indications to include but not limited to the following because the evidence is insufficient to determine that the technology results in an improvement in the net health outcomes: • Asymptomatic/General population screening • Routine testing Frequency Testing: Medically Necessary 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D The evaluation and monitoring of vitamin D may be considered medically necessary when the above criteria has been met, no more frequently than annually. Frequency Testing: Not Medically Necessary 25-hydroxyvitamin D and 1,25- dihydroxyvitamin D The evaluation and monitoring of vitamin D when testing occurs more frequently than annually is considered not medically necessary. POLICY GUIDELINES Note • Iowa House File 2668 (Iowa Code section 514C.36) requires that certain health plans issued or renewed on or after January 1, 2025 “provide coverage for biomarker testing for the purposes of diagnosing, treating, appropriately managing, or monitoring a disease or condition in a covered person when the biomarker testing has demonstrated clinical utility.” Iowa House File 2668 defines clinical utility as” sufficient medical and scientific evidence indicating that the use of a biomarker test will provide meaningful information that affects treatment decisions and guides improvement of net health outcomes, including an improved quality of life or longer survival.” Wellmark has reviewed this Medical Policy in light of Iowa House File 2668. • There are no standardized lists of factors denoting high risk for vitamin D deficiency, and published lists of high-risk factors differ considerably. Certain factors tend to be present on most lists, however, and they may constitute a core set of factors for which there is general agreement that testing is indicated.

Page 5

Wellmark Blue Cross and Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. 5 © Wellmark, Inc. • Serum concentration of 25 hydroxyvitamin D is the optimal clinical indicator of vitamin D metabolism due to the rapid conversion of vitamin D to 25-hydroxyvitamin D with only a small fraction converted to 1,25 hydroxyvitamin D. • Signs and symptoms of vitamin D deficiency are largely manifested by changes in bone health and biochemical markers associated with bone production and resorption. In most cases, a clinical diagnosis of an abnormality in bone health (e.g., rickets, osteomalacia, osteoporosis) will lead to a decision to test vitamin D levels. Symptoms related to the clinical condition may be present (e.g., pain, low-impact fractures), but these symptoms are usually not indications for testing prior to a specific diagnosis. Some biochemical markers of bone health may indicate an increased risk for vitamin D deficiency, and testing of vitamin D levels may, therefore, be appropriate. These biochemical markers include unexplained abnormalities in serum calcium, phosphorus, alkaline phosphatase, and/or parathyroid hormone. • Signs and symptoms of vitamin D toxicity (hypervitaminosis D) generally result from induced hypercalcemia. Acute intoxication can cause symptoms of confusion, anorexia, vomiting, weakness, polydipsia, and polyuria. Chronic intoxication can cause bone demineralization, kidney stones, and bone pain. Definitions • Vitamin D - A nutrient that helps the body absorb calcium in the intestines. Calcium and vitamin D can help prevent bone loss, lower the risk of fracture, and perform other functions in the body. Sources of vitamin D include sun exposure, foods such as fortified dairy products, and dietary supplements. • Vitamin D deficiency - There is too little vitamin D in the blood. Low vitamin D levels can cause problems such as bone loss or softening. Low vitamin D in the blood can be caused by not eating foods that contain vitamin D or not getting enough sun exposure. Low vitamin D can also be caused by certain health conditions, such as some liver, kidney, and intestinal diseases. • “Institutionalized” - as used herein refers to individuals who reside at long-term facilities where some degree of medical care is provided. These circumstances and facilities can include long- term hospital stays, nursing homes, assisted living facilities, and similar environments. • Serum 25-hydroxyvitamin D test for vitamin D – A blood test which measures level of 25- hydroxyvitamin D, a form of Vitamin D that circulates in the body. This form of Vitamin D is considered the most accurate way to determine that the body’s vitamin D levels are too low or too high. It is the test commonly used to measure overall vitamin D levels. • Serum 1,25-dihydroxyvitamin D test for vitamin D - A blood test which measures levels of 1,25- dihydroxyvitamin D, a potent form of vitamin D that is used quickly in the body. It is not considered an accurate way to measure the body’s overall reserves of vitamin D. Measurement of this type of vitamin D is useful for a small number of diseases, such as chronic kidney disease. The CDC Defined Childhood Weight Status: CDC Growth Charts are commonly used to measure the size and growth patterns of children and teens in the United States. BMI-for-age weight status categories and the corresponding percentiles, based on expert committee recommendations, and are in the following table: BMI-for-age weight status categories and the corresponding percentiles Weight Status Category BMI Range Underweight Less than the 5th percentile

Tags

Doxxly editorial guide

02.04.34 Vitamin D Testing: summary, contents and background

This guide helps you understand the scope of 02.04.34 Vitamin D Testing before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

02.04.34 Vitamin D Testing is a 51-page documentcredited to Umar F. Thackery. Wellmark medical policy defining when 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D testing may be considered medically necessary for specified conditions affecting vitamin D metabolism. Testing that meets the policy criteria is limited to no more than annually; more frequent testing is considered not medically necessary. Routine testing and asymptomatic general-population screening are considered investigational. The document includes clinical background, an evidence review, professional guidelines, references, billing codes 82306, 82652, and 0038U, and policy history. Originally effective May 2011, it lists a February 2026 review date and February 2024 revision date. Coverage remains subject to the member’s benefit plan. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Medical policy, Vitamin D testing, Vitamin D deficiency, Laboratory testing, Medical necessity, Insurance coverage, Evidence review with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with Medical policy, Vitamin D testing, Vitamin D deficiency, Laboratory testing, Medical necessity, Insurance coverage, Evidence review. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 51 pages in the player.

  1. Part 1

    Medical policy

    Use this section of the reading guide to identify how Medical policy appears in 02.04.34 Vitamin D Testing, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    Vitamin D testing

    Use this section of the reading guide to identify how Vitamin D testing appears in 02.04.34 Vitamin D Testing, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    Vitamin D deficiency

    Use this section of the reading guide to identify how Vitamin D deficiency appears in 02.04.34 Vitamin D Testing, note important terms, and connect the subject to the wider purpose of the work.

  4. Part 4

    Laboratory testing

    Use this section of the reading guide to identify how Laboratory testing appears in 02.04.34 Vitamin D Testing, note important terms, and connect the subject to the wider purpose of the work.

  5. Part 5

    Medical necessity

    Use this section of the reading guide to identify how Medical necessity appears in 02.04.34 Vitamin D Testing, note important terms, and connect the subject to the wider purpose of the work.

  6. Part 6

    Insurance coverage

    Use this section of the reading guide to identify how Insurance coverage appears in 02.04.34 Vitamin D Testing, note important terms, and connect the subject to the wider purpose of the work.

  7. Part 7

    Evidence review

    Use this section of the reading guide to identify how Evidence review appears in 02.04.34 Vitamin D Testing, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Umar F. Thackery

Doxxly credits Umar F. Thackery as the author or creator of 02.04.34 Vitamin D Testing. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is digital-assets.wellmark.com. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit digital-assets.wellmark.com

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read 02.04.34 Vitamin D Testing, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Explore more Medicine & Wellbeing resources

Frequently asked questions about 02.04.34 Vitamin D Testing

Practical answers about reading, downloading and understanding this document on Doxxly.

More in Medicine & Wellbeing